Cindy Parks Thomas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cindy Parks Thomas has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
Meelee Kim
5 shared publicationsPeter Kreiner
Schneider Institutes for Health Policy Brandeis University Waltham MA USA
4 shared publicationsAlex H.S. Harris
Brandeis University Schneider Institutes for Health Policy (CPT, GAR, DWG); Center for Innovation to Implementation, VA Palo Alto Healthcare System, Stanford School of Medicine (AHSH); Tufts University School of Medicine and Lemuel Shattuck Hospital (KIF); and Commonwealth Care Alliance, Boston, MA (BH)
3 shared publicationsAllen S. Daniels
3 shared publicationsCatherine Anne Fullerton
3 shared publicationsConstance M. Horgan
Heller School for Social Policy and Management Brandeis University Waltham Massachusetts USA
3 shared publications
Latest Publications
- Open Access
- 5 November 2025
- Published by Wiley in Academic Emergency Medicine
- Vol. 33 (2)
The Financial Sustainability of Programs to Initiate Medications for Opioid Use Disorder in Emergency Department Settings
Background: The US is experiencing an epidemic of opioid misuse and mortality. Effective treatments are available, including medications for opioid use disorders (MOUD), but they are greatly underused due to a variety of barriers. In response, some US hospitals have established programs to identify emergency department (ED) patients with opioid use disorders (OUD) and begin treatment with MOUD (“ED induction”). For this model to be widely adopted, financial sustainability for hospitals is critical. Little is known about the financial aspects of ED‐based treatment models, including insurance billing and reimbursement. Objectives: Our study addressed the following questions about ED‐based induction of OUD treatment: (1) Which components of this model are billable to insurers? (2) How do hospitals fund the components that are not billable? (3) Does ED‐based induction generate savings that could help fund that service? Methods: We conducted a qualitative study, involving semi‐structured interviews with officials at selected US hospitals. Potential interviewees were identified using a snowball sampling approach. We conducted 12 interviews across 10 states, mostly with urban teaching hospitals. Results: Key findings include, (1) medication costs are often billable to insurers, but costs of key para‐professional staff like peer navigators are not, requiring the hospital to absorb their salaries. Even some billable costs are reimbursed at low rates which challenge sustainability. (2) To fund non‐billable components, hospitals typically rely on time‐limited grant funding, including the federal 340B drug rebate program. (3) Several interviewees anticipated cost savings to their hospitals from reduced use of ED services by patients who had no (or low‐paying) insurance. Discussion: These findings indicate that some hospitals are able to sustain ED‐based induction of MOUD using time‐limited grant funding. However, wider dissemination of this model will likely require more stable funding streams, such as Medicaid reimbursement, paying adequate rates, and coverage of personnel.
- 5 November 2025
- Published by Wiley in Academic Emergency Medicine
- Vol. 33 (2)
Open AccessThe Financial Sustainability of Programs to Initiate Medications for Opioid Use Disorder in Emergency Department Settings
Background: The US is experiencing an epidemic of opioid misuse and mortality. Effective treatments are available, including medications for opioid use disorders (MOUD), but they are greatly underused due to a variety of barriers. In response, some US hospitals have established programs to identify emergency department (ED) patients with opioid use disorders (OUD) and begin treatment with MOUD (“ED induction”). For this model to be widely adopted, financial sustainability for hospitals is critical. Little is known about the financial aspects of ED‐based treatment models, including insurance billing and reimbursement. Objectives: Our study addressed the following questions about ED‐based induction of OUD treatment: (1) Which components of this model are billable to insurers? (2) How do hospitals fund the components that are not billable? (3) Does ED‐based induction generate savings that could help fund that service? Methods: We conducted a qualitative study, involving semi‐structured interviews with officials at selected US hospitals. Potential interviewees were identified using a snowball sampling approach. We conducted 12 interviews across 10 states, mostly with urban teaching hospitals. Results: Key findings include, (1) medication costs are often billable to insurers, but costs of key para‐professional staff like peer navigators are not, requiring the hospital to absorb their salaries. Even some billable costs are reimbursed at low rates which challenge sustainability. (2) To fund non‐billable components, hospitals typically rely on time‐limited grant funding, including the federal 340B drug rebate program. (3) Several interviewees anticipated cost savings to their hospitals from reduced use of ED services by patients who had no (or low‐paying) insurance. Discussion: These findings indicate that some hospitals are able to sustain ED‐based induction of MOUD using time‐limited grant funding. However, wider dissemination of this model will likely require more stable funding streams, such as Medicaid reimbursement, paying adequate rates, and coverage of personnel.
- Open Access
- 30 April 2025
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 3 (5)
Predictors of non-transport by emergency medical services after a nonfatal opioid overdose: a national analysis
Introduction: Emergency medical services (EMS) response to nonfatal overdoses represents an opportunity to provide linkage to services. However, patients may decline follow-on transportation. This paper examined predictors associated with non-transport after nonfatal opioid overdoses. Methods: We undertook a cross-sectional analysis of 2021-2022 data from the National EMS Information System. The outcome was a binary measure of declined transport. Predictors included age, gender, race/ethnicity, response time, EMS level of care, naloxone does, setting, urbanicity, region, time, and day. Results: We identified 710 263 nonfatal opioid overdose events, of which 12.4% ended in non-transport. Men were more likely to decline transport (average marginal effect [AME] 0.020 [95% CI, 0.019-0.022]), and Black patients were less likely to decline (AME −0.022 [95% CI, −0.024 to −0.021]). Compared with events involving an EMS-administered limited first dose (<2 mg), non-transports were more likely in events without naloxone administration (AME 0.075 [95% CI, 0.073-0.078]), with administration only by laypersons (AME 0.101 [95% CI, 0.096-0.107]), and when EMS administered higher first doses (2-4 mg AME 0.039 [95% CI, 0.037-0.041]; 4 mg+ AME 0.053 [95% CI, 0.049-0.056]). Conclusion: Efforts to improve post-overdose care should focus on groups who are more likely to decline transport and on appropriate naloxone dosing.
- 30 April 2025
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 3 (5)
Open AccessPredictors of non-transport by emergency medical services after a nonfatal opioid overdose: a national analysis
Introduction: Emergency medical services (EMS) response to nonfatal overdoses represents an opportunity to provide linkage to services. However, patients may decline follow-on transportation. This paper examined predictors associated with non-transport after nonfatal opioid overdoses. Methods: We undertook a cross-sectional analysis of 2021-2022 data from the National EMS Information System. The outcome was a binary measure of declined transport. Predictors included age, gender, race/ethnicity, response time, EMS level of care, naloxone does, setting, urbanicity, region, time, and day. Results: We identified 710 263 nonfatal opioid overdose events, of which 12.4% ended in non-transport. Men were more likely to decline transport (average marginal effect [AME] 0.020 [95% CI, 0.019-0.022]), and Black patients were less likely to decline (AME −0.022 [95% CI, −0.024 to −0.021]). Compared with events involving an EMS-administered limited first dose (<2 mg), non-transports were more likely in events without naloxone administration (AME 0.075 [95% CI, 0.073-0.078]), with administration only by laypersons (AME 0.101 [95% CI, 0.096-0.107]), and when EMS administered higher first doses (2-4 mg AME 0.039 [95% CI, 0.037-0.041]; 4 mg+ AME 0.053 [95% CI, 0.049-0.056]). Conclusion: Efforts to improve post-overdose care should focus on groups who are more likely to decline transport and on appropriate naloxone dosing.
- 1 March 2023
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (3) , e232052
Quality of Opioid Use Disorder Treatment for Persons With and Without Disabling Conditions
Importance: Adverse outcomes associated with opioid use disorder (OUD) are disproportionately high among people with disabilities (PWD) compared with those without disability. A gap remains in understanding the quality of OUD treatment for people with physical, sensory, cognitive, and developmental disabilities, specifically regarding medications for OUD (MOUD), a foundation of treatment.Objective: To examine the use and quality of OUD treatment in adults with diagnosed disabling conditions, compared with adults without these diagnoses.Design, Setting, and Participants: This case-control study used Washington State Medicaid data from 2016 to 2019 (for use) and 2017 to 2018 (for continuity). Data were obtained for outpatient, residential, and inpatient settings with Medicaid claims. Participants included Washington State full-benefit Medicaid enrollees aged 18 to 64 years, continuously eligible for 12 months, with OUD during the study years and not enrolled in Medicare. Data analysis was performed from January to September 2022.Exposures: Disability status, including physical (spinal cord injury or mobility impairment), sensory (visual or hearing impairments), developmental (intellectual or developmental disability or autism), and cognitive (traumatic brain injury) disabilities.Main Outcomes and Measures: The main outcomes were National Quality Forum–endorsed quality measures: (1) use of MOUD (buprenorphine, methadone, or naltrexone) during each study year and (2) 6-month continuity of treatment (for those taking MOUD).Results: A total of 84 728 Washington Medicaid enrollees had claims evidence of OUD, representing 159 591 person-years (84 762 person-years [53.1%] for female participants, 116 145 person-years [72.8%] for non-Hispanic White participants, and 100 970 person-years [63.3%] for participants aged 18-39 years); 15.5% of the population (24 743 person-years) had evidence of a physical, sensory, developmental, or cognitive disability. PWD were 40% less likely than those without a disability to receive any MOUD (adjusted odds ratio [AOR], 0.60; 95% CI, 0.58-0.61; P < .001). This was true for each disability type, with variations. Individuals with a developmental disability were least likely to use MOUD (AOR, 0.50; 95% CI, 0.46-0.55; P < .001). Of those using MOUD, PWD were 13% less likely than people without disability to continue MOUD for 6 months (adjusted OR, 0.87; 95% CI, 0.82-0.93; P < .001).Conclusions and Relevance: In this case-control study of a Medicaid population, treatment differences were found between PWD and people without these disabilities; these differences cannot be explained clinically and highlight inequities in treatment. Policies and interventions to increase MOUD access are critical to reducing morbidity and mortality among PWD. Potential solutions include improved enforcement of the Americans with Disabilities Act, workforce best practice training, and addressing stigma, accessibility, and the need for accommodations to improve OUD treatment for PWD.
- 1 March 2023
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (3) , e232052
Quality of Opioid Use Disorder Treatment for Persons With and Without Disabling Conditions
Importance: Adverse outcomes associated with opioid use disorder (OUD) are disproportionately high among people with disabilities (PWD) compared with those without disability. A gap remains in understanding the quality of OUD treatment for people with physical, sensory, cognitive, and developmental disabilities, specifically regarding medications for OUD (MOUD), a foundation of treatment.Objective: To examine the use and quality of OUD treatment in adults with diagnosed disabling conditions, compared with adults without these diagnoses.Design, Setting, and Participants: This case-control study used Washington State Medicaid data from 2016 to 2019 (for use) and 2017 to 2018 (for continuity). Data were obtained for outpatient, residential, and inpatient settings with Medicaid claims. Participants included Washington State full-benefit Medicaid enrollees aged 18 to 64 years, continuously eligible for 12 months, with OUD during the study years and not enrolled in Medicare. Data analysis was performed from January to September 2022.Exposures: Disability status, including physical (spinal cord injury or mobility impairment), sensory (visual or hearing impairments), developmental (intellectual or developmental disability or autism), and cognitive (traumatic brain injury) disabilities.Main Outcomes and Measures: The main outcomes were National Quality Forum–endorsed quality measures: (1) use of MOUD (buprenorphine, methadone, or naltrexone) during each study year and (2) 6-month continuity of treatment (for those taking MOUD).Results: A total of 84 728 Washington Medicaid enrollees had claims evidence of OUD, representing 159 591 person-years (84 762 person-years [53.1%] for female participants, 116 145 person-years [72.8%] for non-Hispanic White participants, and 100 970 person-years [63.3%] for participants aged 18-39 years); 15.5% of the population (24 743 person-years) had evidence of a physical, sensory, developmental, or cognitive disability. PWD were 40% less likely than those without a disability to receive any MOUD (adjusted odds ratio [AOR], 0.60; 95% CI, 0.58-0.61; P < .001). This was true for each disability type, with variations. Individuals with a developmental disability were least likely to use MOUD (AOR, 0.50; 95% CI, 0.46-0.55; P < .001). Of those using MOUD, PWD were 13% less likely than people without disability to continue MOUD for 6 months (adjusted OR, 0.87; 95% CI, 0.82-0.93; P < .001).Conclusions and Relevance: In this case-control study of a Medicaid population, treatment differences were found between PWD and people without these disabilities; these differences cannot be explained clinically and highlight inequities in treatment. Policies and interventions to increase MOUD access are critical to reducing morbidity and mortality among PWD. Potential solutions include improved enforcement of the Americans with Disabilities Act, workforce best practice training, and addressing stigma, accessibility, and the need for accommodations to improve OUD treatment for PWD.
- 11 July 2022
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 141, 108837
Emergency department interventions for opioid use disorder: A synthesis of emerging models
- 11 July 2022
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 141, 108837
Emergency department interventions for opioid use disorder: A synthesis of emerging models
- 1 October 2021
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 129, 108479
Emergency department–based efforts to offer medication treatment for opioid use disorder: What can we learn from current approaches?
- 1 October 2021
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 129, 108479
Emergency department–based efforts to offer medication treatment for opioid use disorder: What can we learn from current approaches?
- 18 May 2021
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 16 (2) , 130-131
Commentary: Moving Toward Clear, Evidence-based, and Effective State Policies for Addiction Medicine
State policies play a critical role in determining health care delivery, health equity, and health outcomes, but vary widely in scope, target, restrictiveness, and goals. Understanding how such policies impact health care is critical to development of evidence-based policies, but difficult in the absence of organized and standardized approaches to analysis. Development of themes and frameworks for analysis, and identification of policies supported by evidence, are important steps in moving toward more rational and aligned policies. Buprenorphine treatment for opioid use disorder provides a good example and methodological foundation. At the same time, state policies are promulgated within a larger policy, treatment, and socio-economic environment, and these influences must be considered as well.
- 18 May 2021
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 16 (2) , 130-131
Commentary: Moving Toward Clear, Evidence-based, and Effective State Policies for Addiction Medicine
State policies play a critical role in determining health care delivery, health equity, and health outcomes, but vary widely in scope, target, restrictiveness, and goals. Understanding how such policies impact health care is critical to development of evidence-based policies, but difficult in the absence of organized and standardized approaches to analysis. Development of themes and frameworks for analysis, and identification of policies supported by evidence, are important steps in moving toward more rational and aligned policies. Buprenorphine treatment for opioid use disorder provides a good example and methodological foundation. At the same time, state policies are promulgated within a larger policy, treatment, and socio-economic environment, and these influences must be considered as well.
- Open Access
- 22 January 2021
- Published by SAGE Publications in Global Advances in Health and Medicine
- Vol. 10
The Impact of Tai Chi Exercise on Health Care Utilization and Imputed Cost in Residents of Low-Income Senior Housing
Background/Objectives: This study was designed to test the impact of Tai Chi (TC) on healthcare utilization and cost in older adults living in low-income senior housing. We hypothesized that TC would improve overall health enough to reduce the use of emergency department (ED) and inpatient services. Design: Cluster randomized controlled trial with randomization at the housing site level. Setting: Greater Boston, Massachusetts. Participants: The study includes 6 sites with 75 individuals in the TC treatment condition and 6 sites with 67 individuals in the health education control condition. Intervention: Members of the treatment group received up to a year-long intervention with twice weekly, in-person TC exercise sessions along with video-directed exercises that could be done independently at home. The comparison group received monthly, in-person healthy aging education classes (HE). Study recruitment took place between August, 2015 and October, 2017. Key outcomes included acute care utilization (inpatient stays, observation stays and emergency department visits). In addition, the cost of utilization was estimated using the age, sex and race adjusted allowed amount from Medicare claims for a geographically similar population aged ≥ 65. Results: The results suggested a possible reduction in the rate of ED visits in the TC group vs. controls (rate ratio = 0.476, p-value = 0.06), but no findings achieved statistical significance. Adjusted estimates of imputed costs of ED and hospital care were similar between TC and HE, averaging approximately $3,000 in each group. Conclusion: ED utilization tended to be lower over 6 to 12 months of TC exercises compared to HE in older adults living in low-income housing, although estimated costs of care were similar.
- 22 January 2021
- Published by SAGE Publications in Global Advances in Health and Medicine
- Vol. 10
Open AccessThe Impact of Tai Chi Exercise on Health Care Utilization and Imputed Cost in Residents of Low-Income Senior Housing
Background/Objectives: This study was designed to test the impact of Tai Chi (TC) on healthcare utilization and cost in older adults living in low-income senior housing. We hypothesized that TC would improve overall health enough to reduce the use of emergency department (ED) and inpatient services. Design: Cluster randomized controlled trial with randomization at the housing site level. Setting: Greater Boston, Massachusetts. Participants: The study includes 6 sites with 75 individuals in the TC treatment condition and 6 sites with 67 individuals in the health education control condition. Intervention: Members of the treatment group received up to a year-long intervention with twice weekly, in-person TC exercise sessions along with video-directed exercises that could be done independently at home. The comparison group received monthly, in-person healthy aging education classes (HE). Study recruitment took place between August, 2015 and October, 2017. Key outcomes included acute care utilization (inpatient stays, observation stays and emergency department visits). In addition, the cost of utilization was estimated using the age, sex and race adjusted allowed amount from Medicare claims for a geographically similar population aged ≥ 65. Results: The results suggested a possible reduction in the rate of ED visits in the TC group vs. controls (rate ratio = 0.476, p-value = 0.06), but no findings achieved statistical significance. Adjusted estimates of imputed costs of ED and hospital care were similar between TC and HE, averaging approximately $3,000 in each group. Conclusion: ED utilization tended to be lower over 6 to 12 months of TC exercises compared to HE in older adults living in low-income housing, although estimated costs of care were similar.
- 1 July 2018
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 12 (4) , 287-294
Applying American Society of Addiction Medicine Performance Measures in Commercial Health Insurance and Services Data
Objectives: ASAM's Standards of Care for the Addiction Specialist established appropriate care for the treatment of substance use disorders. ASAM identified three high priority performance measures for specification and testing for feasibility in various systems using administrative claims: use of pharmacotherapy for alcohol use disorder (AUD); use of pharmacotherapy for opioid use disorder (OUD); and continuity of care after withdrawal management services. This study adds to the initial testing of these measures in the Veteran's Health Administration (VHA) by testing the feasibility of specifications in commercial insurance data (Cigna). Methods: Using 2014 and 2015 administrative data, the proportion of individuals with an AUD or OUD diagnosis each year who filled prescriptions or were dispensed appropriate FDA-approved pharmacotherapy. For withdrawal management follow up, the proportion with an outpatient encounter within seven days was calculated. The sensitivity of specifications was also tested. Results: Rates of pharmacotherapy for AUD ranged from 6.2% to 7.6% (depending on year and specification details), and rates for OUD pharmacotherapy were 25.0% to 29.7%. Seven-day follow up rate after withdrawal management in an outpatient setting was 20.5%, and an additional 39.7% in an inpatient or residential setting. Conclusions: Application of ASAM specifications is feasible in commercial administrative data. Because of varying system needs and payment practices across health systems, measures may require adjustment for different settings. Moving forward, important focus will be on the continued refinement of these measures with the new ICD-10 coding systems, new formulations of current medications, and new payment approaches such as bundled payment.
- 1 July 2018
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 12 (4) , 287-294
Applying American Society of Addiction Medicine Performance Measures in Commercial Health Insurance and Services Data
Objectives: ASAM's Standards of Care for the Addiction Specialist established appropriate care for the treatment of substance use disorders. ASAM identified three high priority performance measures for specification and testing for feasibility in various systems using administrative claims: use of pharmacotherapy for alcohol use disorder (AUD); use of pharmacotherapy for opioid use disorder (OUD); and continuity of care after withdrawal management services. This study adds to the initial testing of these measures in the Veteran's Health Administration (VHA) by testing the feasibility of specifications in commercial insurance data (Cigna). Methods: Using 2014 and 2015 administrative data, the proportion of individuals with an AUD or OUD diagnosis each year who filled prescriptions or were dispensed appropriate FDA-approved pharmacotherapy. For withdrawal management follow up, the proportion with an outpatient encounter within seven days was calculated. The sensitivity of specifications was also tested. Results: Rates of pharmacotherapy for AUD ranged from 6.2% to 7.6% (depending on year and specification details), and rates for OUD pharmacotherapy were 25.0% to 29.7%. Seven-day follow up rate after withdrawal management in an outpatient setting was 20.5%, and an additional 39.7% in an inpatient or residential setting. Conclusions: Application of ASAM specifications is feasible in commercial administrative data. Because of varying system needs and payment practices across health systems, measures may require adjustment for different settings. Moving forward, important focus will be on the continued refinement of these measures with the new ICD-10 coding systems, new formulations of current medications, and new payment approaches such as bundled payment.
- 1 December 2017
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 181, 213-218
Prescribing patterns of buprenorphine waivered physicians
- 1 December 2017
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 181, 213-218
Prescribing patterns of buprenorphine waivered physicians
- 1 September 2017
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 60, 96-104
The Mind Body-Wellness in Supportive Housing (Mi-WiSH) study: Design and rationale of a cluster randomized controlled trial of Tai Chi in senior housing
- 1 September 2017
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 60, 96-104
The Mind Body-Wellness in Supportive Housing (Mi-WiSH) study: Design and rationale of a cluster randomized controlled trial of Tai Chi in senior housing